m+Medelevator.RU
← Поиск публикаций
World journal of surgical oncology · 2026

miR-19a-3p accelerates the development of melanoma and reduces the prognosis of patients.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Kang Ting, Xu Liwei, Wang Gang

Аннотация

BACKGROUND: Previous studies have shown that miR-19a-3p is expressed at higher levels in melanoma tissues, suggesting that it may be involved in the progression of melanoma. This study sought to elucidate the biological function of miR-19a-3p in melanoma. METHODS: In this study, RT-qPCR was performed to measure the expression level of miR-19a-3p in melanoma tissues and cell lines. The relationship between miR-19a-3p and the prognosis of melanoma patients was assessed by Kaplan-Meier analysis and the Cox regression model. The effects of miR-19a-3p on cell proliferation, migration, and invasion were analyzed by Cell Counting Kit-8 (CCK-8) and Transwell assays. The targeting relationship between miR-19a-3p and adrenergic receptor β1 (ADRB1) was verified by Dual-luciferase reporter assay. RESULTS: miR-19a-3p was significantly overexpressed in melanoma tissues and cell lines. The high expression of miR-19a-3p was significantly associated with a higher TNM stage, lymph node metastasis, and decreased survival rate. Inhibition of miR-19a-3p could significantly weaken the proliferation, migration, and invasion abilities of melanoma cells. ADRB1 was a direct target of miR-19a-3p, and their expressions were negatively correlated. Knockdown of ADRB1 reversed the anti-tumor effect of miR-19a-3p inhibitor. CONCLUSION: miR-19a-3p promoted the malignant progression of melanoma by targeting and inhibiting ADRB1. Its expression level can serve as an independent biomarker for evaluating the prognosis of melanoma patients.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты